Literature DB >> 25034349

Capture rate and representativity of The National Prostate Cancer Register of Sweden.

Katarina Tomic1, Anders Berglund, David Robinson, Marie Hjälm-Eriksson, Stefan Carlsson, Mats Lambe, Pär Stattin.   

Abstract

BACKGROUND: Capture rate and representativity of quality registers need to be assessed in order to ensure that register data are generalizable.
MATERIAL AND METHODS: In 1998-2009, 103 047 men had been diagnosed with prostate cancer and registered in the Swedish Cancer Register to which registration is mandated by law and of these men, 100 849 men (98%) had also been registered in The National Prostate Cancer Register (NPCR) of Sweden. We compared demographics, cancer treatment, comorbidity, and mortality in men in NPCR, with those who had only been registered in the Cancer Register, by use of data from the Cause of Death Register, the In-Patient Register and the Prescribed Drug Register. In addition, we identified 1929 men who had prostate cancer as underlying cause of death in the Cause of Death Register who had neither been registered in the Cancer Register nor in NPCR.
RESULTS: Compared to men in NPCR, men only registered in the Cancer Register were slightly older, median age 72 versus 71 years, and a lower proportion underwent radical prostatectomy, 15% versus 27%. Ten year prostate cancer mortality was 23% (95% CI 20-25) for men in the Cancer Register only and 24% (95% CI 24-25) in NPCR, while mortality from competing causes was 28% (95% CI 26-31) and 30% (95% CI 30-30), respectively. Men identified with prostate cancer by a death certificate were old and had high comorbidity.
CONCLUSION: The capture rate of NPCR is very high and there are only modest differences in demographics, cancer treatment, comorbidity, and mortality between the small proportion of men only registered in the Cancer Register and men registered in NPCR, indicating that information in NPCR can be generalized to all men with prostate cancer in Sweden.

Entities:  

Mesh:

Year:  2014        PMID: 25034349     DOI: 10.3109/0284186X.2014.939299

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  17 in total

1.  Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study.

Authors:  Kerri Beckmann; Hans Garmo; Bertil Lindahl; Lars Holmberg; Pär Stattin; Jan Adolfsson; J Kennedy Cruickshank; Mieke Van Hemelrijck
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-03-02       Impact factor: 5.554

2.  Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and retropubic radical prostatectomy: a nationwide population-based study.

Authors:  Johan Björklund; Yasin Folkvaljon; Alexander Cole; Stefan Carlsson; David Robinson; Stacy Loeb; Pär Stattin; Olof Akre
Journal:  BJU Int       Date:  2016-02-15       Impact factor: 5.588

3.  Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.

Authors:  Frederik B Thomsen; Yasin Folkvaljon; Klaus Brasso; Stacy Loeb; David Robinson; Lars Egevad; Pär Stattin
Journal:  J Surg Oncol       Date:  2016-08-11       Impact factor: 3.454

4.  Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

Authors:  Stacy Loeb; Yasin Folkvaljon; Caitlin Curnyn; David Robinson; Ola Bratt; Pär Stattin
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

5.  Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study.

Authors:  Renata Zelic; Daniela Zugna; Matteo Bottai; Ove Andrén; Jonna Fridfeldt; Jessica Carlsson; Sabina Davidsson; Valentina Fiano; Michelangelo Fiorentino; Francesca Giunchi; Chiara Grasso; Luca Lianas; Cecilia Mascia; Luca Molinaro; Gianluigi Zanetti; Lorenzo Richiardi; Andreas Pettersson; Olof Akre
Journal:  Am J Epidemiol       Date:  2019-06-01       Impact factor: 4.897

6.  Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery.

Authors:  Eugenio Ventimiglia; Yasin Folkvaljon; Stefan Carlsson; Ola Bratt; Francesco Montorsi; Daniela Volz; Olof Akre; Eva Johansson; Pär Stattin
Journal:  J Surg Oncol       Date:  2017-09-06       Impact factor: 3.454

7.  Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

Authors:  Stacy Loeb; Yasin Folkvaljon; Jan-Erik Damber; Joseph Alukal; Mats Lambe; Pär Stattin
Journal:  J Clin Oncol       Date:  2017-03-13       Impact factor: 44.544

8.  The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study.

Authors:  V J Gnanapragasam; O Bratt; K Muir; L S Lee; H H Huang; P Stattin; A Lophatananon
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

9.  Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer.

Authors:  Richard Shore; Jingru Yu; Weimin Ye; Jesper Lagergren; Martin Rutegård; Olof Akre; Pär Stattin; Mats Lindblad
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

10.  Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study.

Authors:  Jón Ö Fridriksson; Yasin Folkvaljon; Per Nilsson; David Robinson; Ingela Franck-Lissbrant; Behfar Ehdaie; James A Eastham; Anders Widmark; Camilla T Karlsson; Pär Stattin
Journal:  Scand J Urol       Date:  2016-06-22       Impact factor: 1.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.